Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5G-PEARL: Paxalisib + Temozolomide in High Grade Malignant Brain Tumours
NCT07391215Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paxalisib in glioblastoma (GBM) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 24 months and Preliminary antitumour activity at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
paxalisib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07391215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391215.